One68 Global Capital LLC Takes $1.09 Million Position in Surmodics, Inc. (NASDAQ:SRDX)

One68 Global Capital LLC acquired a new stake in Surmodics, Inc. (NASDAQ:SRDX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 27,457 shares of the company's stock, valued at approximately $1,087,000. One68 Global Capital LLC owned 0.19% of Surmodics as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in SRDX. Modus Advisors LLC acquired a new stake in Surmodics during the fourth quarter worth approximately $40,000. R Squared Ltd acquired a new stake in Surmodics during the 4th quarter worth approximately $55,000. Legal & General Group Plc boosted its stake in Surmodics by 34.2% in the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock valued at $137,000 after purchasing an additional 880 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in Surmodics in the 4th quarter valued at $217,000. Finally, Polymer Capital Management US LLC bought a new position in Surmodics during the 4th quarter worth $255,000. 96.63% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SRDX has been the topic of a number of recent research reports. Lake Street Capital raised shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price target on the stock in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Finally, StockNews.com initiated coverage on Surmodics in a research report on Monday, February 3rd. They set a "hold" rating on the stock. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $43.00.

Surmodics Price Performance

Shares of NASDAQ SRDX traded down $0.73 during trading hours on Monday, hitting $26.92. 24,866 shares of the stock were exchanged, compared to its average volume of 277,208. Surmodics, Inc. has a 1-year low of $26.00 and a 1-year high of $42.44. The company has a market cap of $384.86 million, a PE ratio of -26.64 and a beta of 1.32. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45. The company's fifty day simple moving average is $29.43 and its two-hundred day simple moving average is $34.86.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The business had revenue of $28.09 million during the quarter, compared to analyst estimates of $32.23 million. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. On average, sell-side analysts predict that Surmodics, Inc. will post 0.2 EPS for the current year.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).